Cita APA

Wermke, M., Felip, E., Gambardella, V., Kuboki, Y., Morgensztern, D., Hamed, Z., . . . Owonikoko, T. (2022). Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.

Citación estilo Chicago

Wermke, M., E. Felip, V. Gambardella, Y. Kuboki, D. Morgensztern, ZO Hamed, MR Liu, M. Studeny, y TK Owonikoko. Phase I Trial of the DLL3/CD3 Bispecific T-cell Engager BI 764532 in DLL3-positive Small-cell Lung Cancer and Neuroendocrine Carcinomas. 2022.

Cita MLA

Wermke, M., et al. Phase I Trial of the DLL3/CD3 Bispecific T-cell Engager BI 764532 in DLL3-positive Small-cell Lung Cancer and Neuroendocrine Carcinomas. 2022.